Advancements in Targeted Nanoparticle-Based Drug Delivery Systems: Improving Therapeutic Outcomes in Oncology

Cancer continues to be one of the primary causes of illness and death across the globe, with standard treatment methods often constrained by limited specificity and systemic toxicity. Recent developments in nanotechnology have transformed the field of oncology by creating nanoparticle-based drug delivery systems aimed at enhancing therapeutic accuracy and results. Due to their adjustable size, surface properties, and material composition, nanoparticles facilitate both passive and active targeting of tumours, promoting drug concentration in cancerous tissues while reducing harm to healthy cells. A range of nanoparticle platforms including polymeric nanoparticles, liposomes, micelles, nanogels, and inorganic carriers has been investigated for controlled release, enhanced bioavailability, and targeted therapeutic effects. Nonetheless, challenges such as immune clearance, stability, safety concerns, and large-scale manufacturing pose significant barriers to clinical application. This review emphasizes recent progress in nanoparticle design, targeting methods, and clinical uses, while also discussing the challenges that need to be addressed to fully harness the promise of nanomedicine in cancer treatment.